Vectura Group (LON:VEC)‘s stock had its “overweight” rating reiterated by stock analysts at JPMorgan Chase & Co. in a research note issued on Monday.

Other analysts have also recently issued research reports about the stock. Shore Capital reiterated a “buy” rating on shares of Vectura Group in a research note on Thursday, January 4th. Numis Securities reiterated a “buy” rating and issued a GBX 170 ($2.31) price objective on shares of Vectura Group in a research note on Thursday, January 4th. Panmure Gordon reiterated a “buy” rating and issued a GBX 150 ($2.03) price objective on shares of Vectura Group in a research note on Thursday, November 9th. Citigroup dropped their price objective on shares of Vectura Group from GBX 200 ($2.71) to GBX 180 ($2.44) and set a “buy” rating for the company in a research note on Monday, September 18th. Finally, Peel Hunt reiterated a “hold” rating and issued a GBX 160 ($2.17) price objective on shares of Vectura Group in a research note on Wednesday, November 15th. Three investment analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company’s stock. Vectura Group currently has an average rating of “Buy” and an average target price of GBX 174 ($2.36).

Shares of Vectura Group (VEC) traded up GBX 2.90 ($0.04) during trading on Monday, reaching GBX 119.20 ($1.62). 7,731,120 shares of the company’s stock traded hands, compared to its average volume of 3,890,000. Vectura Group has a twelve month low of GBX 86.50 ($1.17) and a twelve month high of GBX 166.97 ($2.26).

COPYRIGHT VIOLATION WARNING: This article was first published by American Banking News and is the sole property of of American Banking News. If you are reading this article on another site, it was stolen and reposted in violation of U.S. and international trademark and copyright legislation. The legal version of this article can be viewed at https://www.americanbankingnews.com/2018/01/15/vectura-groups-vec-overweight-rating-reiterated-at-jpmorgan-chase-co.html.

About Vectura Group

Vectura Group plc is engaged in research, development and commercialization of therapeutic products and drug delivery systems for human use. The Company’s products include Ultibro Breezhaler (European Union (EU) and Rest of World (RoW)) – LABA-LAMA; Seebri Breezhaler (EU and RoW) – LAMA; AirFluSal Forspiro (EU and RoW) – ICS-LABA; ADVATE (Global) – Antihaemophilic Factor (Recombinant); Adept (Global) – Icodextrin; Anoro Ellipta (Global) – LAMA-LABA; Relvar Ellipta/Breo Ellipta (Global) – ICS-LABA, and Incruse Ellipta (Global) – LAMA.

Analyst Recommendations for Vectura Group (LON:VEC)

Receive News & Ratings for Vectura Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vectura Group and related companies with MarketBeat.com's FREE daily email newsletter.